Clene (CLNN) Competitors

Alpha Cognition has higher revenue and earnings than Clene. Alpha Cognition is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

In the previous week, Alpha Cognition had 4 more articles in the media than Clene. MarketBeat recorded 5 mentions for Alpha Cognition and 1 mentions for Clene. Alpha Cognition's average media sentiment score of 0.59 beat Clene's score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the media.

Alpha Cognition has a beta of 2.32, suggesting that its stock price is 132% more volatile than the broader market. Comparatively, Clene has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

Alpha Cognition has a net margin of -153.61% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Alpha Cognition's return on equity.

23.3% of Clene shares are held by institutional investors. 8.6% of Alpha Cognition shares are held by insiders. Comparatively, 28.3% of Clene shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Alpha Cognition currently has a consensus target price of $18.00, suggesting a potential upside of 99.12%. Clene has a consensus target price of $34.00, suggesting a potential upside of 780.83%. Given Clene's higher possible upside, analysts plainly believe Clene is more favorable than Alpha Cognition.

23.3% of Clene shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 28.3% of Clene shares are owned by company insiders. Comparatively, 14.5% of Journey Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Journey Medical has higher revenue and earnings than Clene. Journey Medical is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

In the previous week, Journey Medical had 2 more articles in the media than Clene. MarketBeat recorded 3 mentions for Journey Medical and 1 mentions for Clene. Journey Medical's average media sentiment score of 0.42 beat Clene's score of 0.00 indicating that Journey Medical is being referred to more favorably in the news media.

Clene has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

Journey Medical has a net margin of -8.95% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Journey Medical's return on equity.

Clene presently has a consensus target price of $34.00, indicating a potential upside of 780.83%. Journey Medical has a consensus target price of $14.00, indicating a potential upside of 121.87%. Given Clene's stronger consensus rating and higher possible upside, analysts plainly believe Clene is more favorable than Journey Medical.

Zentalis Pharmaceuticals currently has a consensus price target of $7.50, suggesting a potential upside of 184.09%. Clene has a consensus price target of $34.00, suggesting a potential upside of 780.83%. Given Clene's stronger consensus rating and higher possible upside, analysts clearly believe Clene is more favorable than Zentalis Pharmaceuticals.

Clene has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Zentalis Pharmaceuticals has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market. Comparatively, Clene has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

In the previous week, Zentalis Pharmaceuticals had 9 more articles in the media than Clene. MarketBeat recorded 10 mentions for Zentalis Pharmaceuticals and 1 mentions for Clene. Zentalis Pharmaceuticals' average media sentiment score of 0.33 beat Clene's score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

23.3% of Clene shares are held by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are held by company insiders. Comparatively, 28.3% of Clene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Zentalis Pharmaceuticals has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 28.3% of Clene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Cardiol Therapeutics and Cardiol Therapeutics both had 1 articles in the media. Cardiol Therapeutics' average media sentiment score of 0.00 equaled Clene'saverage media sentiment score.

Cardiol Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, Clene has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

Cardiol Therapeutics has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Cardiol Therapeutics has higher earnings, but lower revenue than Clene. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Cardiol Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 713.01%. Clene has a consensus price target of $34.00, indicating a potential upside of 780.83%. Given Clene's stronger consensus rating and higher probable upside, analysts plainly believe Clene is more favorable than Cardiol Therapeutics.